The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwAL 2025 | Clonal tracking for patients at risk of developing therapy-related myeloid neoplasms
Koichi Takahashi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the integration of clonal tracking into clinical decision-making for patients at risk of developing therapy-related myeloid neoplasms, to provide detailed insights into clonal evolution. He suggests that with the right molecular pathologist and educational efforts, clinicians can effectively interpret and utilize these results, but acknowledges that overwhelming physicians with data is a potential concern. This interview took place at the 7th International Workshop on Acute Leukemias (iwAL 2025), held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Clonal tracking would be really an interesting aspect. And from a scientific perspective, I think single-cell DNA sequencing will be really powerful in terms of clonal tracking because we can see how these high-risk p53 mutated clones, whether they acquire additional allele abnormalities or not. And that’s only possible through single-cell DNA sequencing. So from a scientific perspective, I think we would like to see single-cell DNA sequencing being incorporated in clonal tracking...
Clonal tracking would be really an interesting aspect. And from a scientific perspective, I think single-cell DNA sequencing will be really powerful in terms of clonal tracking because we can see how these high-risk p53 mutated clones, whether they acquire additional allele abnormalities or not. And that’s only possible through single-cell DNA sequencing. So from a scientific perspective, I think we would like to see single-cell DNA sequencing being incorporated in clonal tracking. Whether that’s going to overwhelm the clinician or not, that’s something that I think we have to see. But, you know, if we have a nice molecular pathologist who can really produce kind of intuitive reports for the clinicians to interpret those results, I think that can be possible. Every physician these days needs to really get used to interpreting and understand more about genomic interpretation. And this is something as a field that we need to maybe ramp up the educational activities to all community physicians to correctly interpret and understand the genetic reports that are produced from these genetic sequencing analyses.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
